{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:50Z","timestamp":1787004830905,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1053\/j.semnuclmed.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T05:00:23Z","timestamp":1509944423000},"page":"37-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["PET\/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up"],"prefix":"10.1053","volume":"48","author":[{"given":"Shawn","family":"Karls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0020","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0025","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0030","first-page":"131","article-title":"The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma","volume":"2","author":"Hosein","year":"2010","journal-title":"European J Clin Med Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0035","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0045","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0050","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0055","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"Tsukamoto","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0060","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1617-0830.2007.00084.x","article-title":"Malignant B-cell lymphoma, WHO classification and the respective 18F-fluoro-deoxy-glucose positron emission tomography results","volume":"10","author":"Hoffmann","year":"2007","journal-title":"Imaging Dec MRI"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0075","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0080","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V86.9.3522.bloodjournal8693522","article-title":"Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose","volume":"86","author":"Lapela","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0085","first-page":"1790","article-title":"Predicting malignancy grade with PET in non-Hodgkin's lymphoma","volume":"36","author":"Rodriguez","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0090","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0100","author":"National Cancer Institute: PDQ\u00ae"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0105","author":"Zelenetz"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation-2009.1.523","article-title":"The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/j.semdp.2011.02.006","article-title":"Pathobiology and diagnosis of follicular lymphoma","volume":"28","author":"Klapper","year":"2011","journal-title":"Semin Diagn Pathol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival\u2014A study from the groupe d'etude des lymphomes de l'adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0135","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","article-title":"Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma","volume":"48","author":"Bishu","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2003.n.013","article-title":"Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma","volume":"4","author":"Blum","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2012.41.7527","article-title":"Curability of advanced indolent or low-grade follicular lymphomas: Time for a new paradigm?","volume":"31","author":"Cabanillas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0150","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdg011","article-title":"Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease","volume":"14","author":"Jerusalem","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0160","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","article-title":"Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?","volume":"8","author":"Janikova","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0165","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.17219\/acem\/31804","article-title":"PET\/CT assessment of follicular lymphoma and high grade B cell lymphoma\u2014Good correlation with clinical and histological features at diagnosis","volume":"24","author":"Novelli","year":"2015","journal-title":"Adv Clin Exp Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0175","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","article-title":"Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma","volume":"7","author":"Zinzani","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0185","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1158\/1078-0432.CCR-13-1511","article-title":"End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: A systematic review and meta-analysis","volume":"19","author":"Pyo","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl 5","key":"10.1053\/j.semnuclmed.2017.09.004_bib0190","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","article-title":"SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma","volume":"88","author":"Zinzani","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0200","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1053\/j.semnuclmed.2017.09.004_bib0205","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.moh.0000138682.13354.da","article-title":"Mantle cell lymphoma","volume":"11","author":"Bertoni","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.2009.140","article-title":"Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms","volume":"23","author":"Chen","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0225","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0230","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/blood.V88.11.4085.bloodjournal88114085","article-title":"Lymphoma classification\u2014The gap between biology and clinical management is closing","volume":"88","author":"Hiddemann","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0235","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0240","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0245","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0250","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0255","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: Treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0265","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/CLM.2008.n.019","article-title":"[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma","volume":"8","author":"Gill","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0270","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma","volume":"28","author":"Dreyling","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0275","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0280","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190802216707","article-title":"Positron emission tomography in mantle cell lymphoma","volume":"49","author":"Brepoels","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0285","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/MNM.0b013e32832e0c13","article-title":"FDG positron emission tomography\/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome","volume":"30","author":"Karam","year":"2009","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0290","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD","volume":"118","author":"Mato","year":"2012","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0295","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","article-title":"Utility of positron emission tomography scans in mantle cell lymphoma","volume":"86","author":"Hosein","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0300","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","article-title":"Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma?","volume":"55","author":"Kedmi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0305","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0310","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0315","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0320","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0325","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0330","author":"Zelenetz"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0335","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdm265","article-title":"FDG-PET in T-cell and NK-cell neoplasms","volume":"18","author":"Kako","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0340","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"suppl 5","key":"10.1053\/j.semnuclmed.2017.09.004_bib0345","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0350","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: Complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0355","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy (1)(8)F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0360","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.112.110262","article-title":"Prognostic value of interim and posttherapy 18F-FDG PET\/CT in patients with mature T-cell and natural killer cell lymphomas","volume":"54","author":"Li","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0365","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12149-015-0964-8","article-title":"Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET\/CT in extranodal natural killer\/T-cell lymphoma, nasal type","volume":"29","author":"Jiang","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0370","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","article-title":"18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: A study from the GOELAMS group","volume":"22","author":"Cahu","year":"2011","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2017.09.004_bib0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hon.2396","article-title":"The role of stem cell transplant for lymphoma in 2017","volume":"35","author":"Gribben","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0380","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0385","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0390","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0395","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2005-11-006957","article-title":"Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma","volume":"109","author":"Schot","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1179\/102453310X12583347009739","article-title":"Predictive value of (18)F-FDG hybrid PET\/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation","volume":"15","author":"Qiao","year":"2010","journal-title":"Hematology"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0405","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0410","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1705416","article-title":"Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation","volume":"38","author":"Svoboda","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0415","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/ejh.12837","article-title":"Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: Systematic review and meta-analysis","volume":"98","author":"Adams","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0420","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: Systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0425","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study","volume":"33","author":"El-Galaly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0430","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.23688","article-title":"Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma","volume":"89","author":"El-Galaly","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0435","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.14694\/EdBook_AM.2014.34.e388","article-title":"Surveillance imaging for lymphoma: Pros and cons","author":"Lynch","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0440","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.mph.0000212912.37512.b1","article-title":"Utility of FDG-PET\/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma","volume":"28","author":"Rhodes","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0445","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.mph.0000243648.66734.eb","article-title":"Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate","volume":"28","author":"Levine","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0450","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3324\/haematol.2011.056010","article-title":"Positron emission tomography\/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs","volume":"97","author":"El-Galaly","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0455","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdp522","article-title":"Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: A retrospective study","volume":"21","author":"Mocikova","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0460","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1148\/radiol.14132154","article-title":"Advanced-stage Hodgkin lymphoma: US\/chest radiography for detection of relapse in patients in first complete remission\u2014A randomized trial of routine surveillance imaging procedures","volume":"272","author":"Picardi","year":"2014","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0465","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1200\/JCO.2008.16.1513","article-title":"Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma","volume":"27","author":"Zinzani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0470","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/annonc\/mdq015","article-title":"Risk-adapted FDG-PET\/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy","volume":"21","author":"Petrausch","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0475","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/10428194.2010.547642","article-title":"Efficacy of routine surveillance with positron emission tomography\/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: Status in a single center","volume":"52","author":"El-Galaly","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0480","first-page":"411","article-title":"Integration of CT-based measurements into surveillance PET\/CT in patients with diffuse large B cell lymphoma","volume":"18","author":"Lavi","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0485","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00277-010-1044-8","article-title":"The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma","volume":"90","author":"Goldschmidt","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0490","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/annonc\/mdl049","article-title":"Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population","volume":"17","author":"Liedtke","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0495","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0500","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3109\/10428194.2013.869801","article-title":"Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"55","author":"Conte","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0505","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0510","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0515","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0520","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/archinte.163.17.1997","article-title":"Posttransplantation lymphoproliferative disorders","volume":"163","author":"Andreone","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0525","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejrad.2007.01.007","article-title":"Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: A possible role for [18F]-FDG-PET(\/CT) in initial staging and therapy monitoring","volume":"63","author":"von Falck","year":"2007","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0530","first-page":"1189","article-title":"PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation","volume":"50","author":"Noraini","year":"2009","journal-title":"Singapore Med J"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0535","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MNM.0000000000000050","article-title":"(18)F-FDG PET\/CT in the management of patients with post-transplant lymphoproliferative disorder","volume":"35","author":"Takehana","year":"2014","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0540","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/TP.0b013e3181661676","article-title":"Clinical usefulness of FDG-PET\/CT scan imaging in the management of posttransplant lymphoproliferative disease","volume":"85","author":"Bianchi","year":"2008","journal-title":"Transplantation"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0545","doi-asserted-by":"crossref","first-page":"20150844","DOI":"10.1259\/bjr.20150844","article-title":"FDG-PET\/CT in abdominal post-transplant lymphoproliferative disease","volume":"89","author":"Metser","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.004_bib0550","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/j.1600-6143.2006.01358.x","article-title":"How useful is PET\/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation?","volume":"6","author":"McCormack","year":"2006","journal-title":"Am J Transplant"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:50:41Z","timestamp":1603241441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299817300818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0001299817300818"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}